Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological and immunological diseases
The company is committed to addressing unmet medical needs by leveraging its expertise in drug development and dermatology to create novel treatment options. Aclaris's research portfolio includes a range of potential therapies aimed at conditions such as alopecia areata and other skin disorders, utilizing both small molecules and biologics to enhance patient care and improve quality of life. Through its dedication to scientific advancement and patient-centered approaches, Aclaris strives to make a meaningful impact in the field of dermatology.
Explore December 23's top pre-market picks, macro insights, and Santa Rally opportunities with StoryTrading's 4-pillar strategy. Join the community for exclusive trade ideas!
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Shares of CommScope Holding Company, Inc. (NASDAQCOMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday.
Shares of Coherus BioSciences, Inc. (NASDAQCHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris reiterates business plans for ongoing programs.
